The NCPE recommends that andexanet alfa (Ondexxya®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Following assessment of the company submission, the NCPE recommend that enzalutamide (Xtandi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*

The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.

Version 2.1 of the Rapid Review Submission templates includes a requirement to submit the NCPE Budget Impact Model Template for all Rapid Review submissions. Version 2.1 of this template was published on 07 April 2022 and replaces version 2.0. Submissions using the old template (version 2.0) will be accepted until 12 May 2022.

The NCPE recommends that risdiplam not be considered for reimbursement until cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that inclisiran (Leqvio®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that apalutamide (Erleada®) in combination with androgen deprivation therapy be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that inotersen be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that encorafenib, in combination with cetuximab, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Notice for Applicants: Please refer to updated versions of the Guidelines for Inclusion of Drug Costs v3.1, Applicant submission template v2. and the Budget Impact Model Template v1.5 when making submissions.